SEC Form 4 · accession 0001193125-26-281059
Relay Therapeutics, Inc. · RLAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Donald A Bergstrom
Officer — President, R&D
Period of report
Jun 22, 2026
Accepted (ET)
Jun 24, 2026 · 4:09 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001812364
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 22, 2026 | M | 93,456 | $4.12 | A | 512,013 | D | |
| Common StockF3,F2 | Jun 22, 2026 | S | 93,456 | $16.94 | D | 418,557 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $4.12 | Jun 22, 2026 | M | 93,456 | D | — | Apr 9, 2028 | Common Stock | 93,456 | 0 | D |
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
- F2Includes 15,037 shares underlying restricted stock units.
- F3This transaction was executed in multiple trades at prices ranging from $16.15 to $17.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4Twenty-five percent (25%) of the shares underlying this option vested on April 2, 2019 and the remainder vested in equal quarterly installments over the remaining thirty-six (36) months.